Top 5 Drug Type | Count |
---|---|
Small molecule drug | 20 |
AAV based gene therapy | 2 |
Fluorescent dyes | 1 |
Monoclonal antibody | 1 |
siRNA | 1 |
Target |
Mechanism CFB inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date05 Dec 2023 |
Target |
Mechanism c-Met inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 May 2020 |
Start Date28 May 2024 |
Sponsor / Collaborator |
Start Date15 Mar 2023 |
Sponsor / Collaborator |
Start Date27 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Olopatadine Hydrochloride ( H1 receptor ) | Allergic rhinoconjunctivitis More | Approved |
Fluorescein Sodium | Uveal Diseases More | Approved |
Nilotinib Hydrochloride ( Bcr-Abl x CSF-1R x DDR1 x PDGFR x c-Kit ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Approved |
Glycopyrrolate ( mAChRs ) | Pulmonary Disease, Chronic Obstructive More | Approved |
Secukinumab ( IL-17A ) | Arthritis, Psoriatic More | Approved |